New data on Vitrakvi(r) (larotrectinib) in TRK fusion cancer patients with brain metastases or primary central nervous system (CNS) tumors

Source :: Plus Company Updates. June 4, 2019
Publication Year :: 2019
Abstract: WHIPPANY: Bayer has issued the following press release: Bayer today announced results of a new analysis from clinical trials investigating Vitrakvi(r) (larotrectinib) in patients with TRK fusion cancer with primary [...]

Subjects :: Bayer AG
Gliomas -- Care and treatment -- Analysis
Medical research -- Analysis
Central nervous system -- Analysis
Pharmaceutical industry -- Analysis
Cancer patients -- Care and treatment -- Analysis
Cancer metastasis -- Care and treatment -- Analysis
Brain tumors -- Care and treatment -- Analysis
Public relations
Clinical trials
Tumors
Glioblastomas
General interest
News, opinion and commentary
Vitrakvi (Medication)

Tools